Bellicum
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3730 Kirby Dr Ste 1200, Houston, Texas, ...Phone Number
(281) 454-3424Website
www.bellicum.comRevenue
<$5 MillionStock Symbol
BLCMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Bellicum
Bellicum conducts research on and develops pharmaceutical solutions in the scope of cellular immuno-oncology. This company is headquartered in Houston, Texas and was established in 2004.Explore more
Bellicum Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bellicum your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Bellicum launches new products
Website visits: Recent activity has been detected on your website
Bellicum, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Bellicum had a recent Job posting/layoffs
Check out if Bellicum is spiking on competitors!
Earning: See what the market has to say on Bellicum recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Bellicum
Check if Bellicum has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Bellicum has new funding data
Recommended Actions
Find VP level buyers at Bellicum
Find 3 more new buyers
Compare Similar Companies to Bellicum
Compare insights from companies similar to Bellicum, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bellicum is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bellicum is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bellicum.
Bellicum financials insights
Gather financial insights about Bellicum, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series B
$20M
2014
Series C
$55M
Stock Offering
$160.6M
2016
Grant
$16.9M
2017
Stock Offering
$69M
2019
Stock Offering
$57.5M
2020
Debt
$2M
2021
Share Placement
$35M
Bellicum Tech Stack
A closer look at the technologies used by Bellicum
See more technologies
Most Recent Scoops
Funding
New Hire
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Aaron Foster, Vice President, Ph D Ph D Product Discovery, has left the organization.
Open Position
Seeking Replacement, Personnel Moves
Bellicum News & Media
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patientsCORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows:Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment withBellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for today at 6 p.m. CT, will provide da
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Bellicum
Sign Up For FreeTo access detailed company insights
Bellicum conducts research on and develops pharmaceutical solutions in the scope of cellular immuno-oncology. This company is headquartered in Houston, Texas and was established in 2004.... Read More
